ARGUN AKCAKANAT to Female
This is a "connection" page, showing publications ARGUN AKCAKANAT has written about Female.
Connection Strength
0.155
-
Genomic, Transcriptomic, and Proteomic Profiling of Metastatic Breast Cancer. Clin Cancer Res. 2021 06 01; 27(11):3243-3252.
Score: 0.021
-
The rapamycin-regulated gene expression signature determines prognosis for breast cancer. Mol Cancer. 2009 Sep 24; 8:75.
Score: 0.009
-
Comparison of Akt/mTOR signaling in primary breast tumors and matched distant metastases. Cancer. 2008 Jun; 112(11):2352-8.
Score: 0.009
-
Heterogeneous expression of GAGE, NY-ESO-1, MAGE-A and SSX proteins in esophageal cancer: Implications for immunotherapy. Int J Cancer. 2006 Jan 01; 118(1):123-8.
Score: 0.007
-
NY-ESO-1 expression and its serum immunoreactivity in esophageal cancer. Cancer Chemother Pharmacol. 2004 Jul; 54(1):95-100.
Score: 0.007
-
Efficacy of futibatinib, an irreversible fibroblast growth factor receptor inhibitor, in FGFR-altered breast cancer. Sci Rep. 2023 11 18; 13(1):20223.
Score: 0.006
-
Diagnostic criteria of colospasm at barium enema examination. Acta Radiol. 2002 Nov; 43(6):629-30.
Score: 0.006
-
Combined MEK/MDM2 inhibition demonstrates antitumor efficacy in TP53 wild-type thyroid and colorectal cancers with MAPK alterations. Sci Rep. 2022 01 24; 12(1):1248.
Score: 0.006
-
Oxidative Phosphorylation Is a Metabolic Vulnerability in Chemotherapy-Resistant Triple-Negative Breast Cancer. Cancer Res. 2021 11 01; 81(21):5572-5581.
Score: 0.005
-
First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer models. Breast Cancer Res. 2021 03 04; 23(1):29.
Score: 0.005
-
Inflammatory response to open tension-free inguinal hernioplasty versus conventional repair. Am J Surg. 2000 Jan; 179(1):76.
Score: 0.005
-
Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation. Breast Cancer Res. 2019 07 05; 21(1):78.
Score: 0.005
-
A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors. Clin Cancer Res. 2017 Nov 01; 23(21):6468-6477.
Score: 0.004
-
Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer. Breast Cancer Res. 2017 Aug 15; 19(1):93.
Score: 0.004
-
Evaluation of trauma care in a developing country highlighted by a major aircraft accident. Eur J Emerg Med. 1997 Jun; 4(2):97-102.
Score: 0.004
-
Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes. PLoS One. 2015; 10(9):e0136851.
Score: 0.004
-
Epithelial to mesenchymal transition is associated with rapamycin resistance. Oncotarget. 2015 Aug 14; 6(23):19500-13.
Score: 0.004
-
SU2C phase Ib study of paclitaxel and MK-2206 in advanced solid tumors and metastatic breast cancer. J Natl Cancer Inst. 2015 Mar; 107(3).
Score: 0.003
-
Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors. Oncotarget. 2014 Sep 30; 5(18):8544-57.
Score: 0.003
-
Influence of biospecimen variables on proteomic biomarkers in breast cancer. Clin Cancer Res. 2014 Jul 15; 20(14):3870-83.
Score: 0.003
-
Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer?. Ann Oncol. 2014 Jun; 25(6):1122-7.
Score: 0.003
-
Colocalized delivery of rapamycin and paclitaxel to tumors enhances synergistic targeting of the PI3K/Akt/mTOR pathway. Mol Ther. 2014 Jul; 22(7):1310-1319.
Score: 0.003
-
PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res. 2014 Apr; 2(4):361-70.
Score: 0.003
-
Weekly nab-Rapamycin in patients with advanced nonhematologic malignancies: final results of a phase I trial. Clin Cancer Res. 2013 Oct 01; 19(19):5474-84.
Score: 0.003
-
High stearoyl-CoA desaturase 1 expression is associated with shorter survival in breast cancer patients. Breast Cancer Res Treat. 2013 Jan; 137(1):319-27.
Score: 0.003
-
Aberrations in translational regulation are associated with poor prognosis in hormone receptor-positive breast cancer. Breast Cancer Res. 2012 Oct 26; 14(5):R138.
Score: 0.003
-
Biomarkers of response to Akt inhibitor MK-2206 in breast cancer. Clin Cancer Res. 2012 Oct 15; 18(20):5816-28.
Score: 0.003
-
PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors. Clin Cancer Res. 2012 Mar 15; 18(6):1777-89.
Score: 0.003
-
The effect of leucine restriction on Akt/mTOR signaling in breast cancer cell lines in vitro and in vivo. Nutr Cancer. 2011; 63(2):264-71.
Score: 0.003
-
Rapamycin regulates stearoyl CoA desaturase 1 expression in breast cancer. Mol Cancer Ther. 2010 Oct; 9(10):2770-84.
Score: 0.003
-
Regulation and localization of ribosomal protein S6 kinase 1 isoforms. Growth Factors. 2009 Feb; 27(1):12-21.
Score: 0.002
-
eIF4E knockdown decreases breast cancer cell growth without activating Akt signaling. Mol Cancer Ther. 2008 Jul; 7(7):1782-8.
Score: 0.002